American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support

Kirklin, James K.; Goldstein, Daniel J.; Atluri, Pavan; Arabía, Francisco A.; Cheung, Anson; Holman, William L.; Hoopes, Charles W.; Jeevanandam, V.; John, Ranjit; Jorde, Ulrich P.; Milano, Carmelo A.; Moazami, Nader; Naka, Yoshifumi; Netuka, Ivan; Pagani, Francis D.; Pamboukian, Salpy V.; Pinney, Sean; Rogers, Joseph G.; Selzman, Craig H.; Silverstry, Scott; Slaughter, Mark S.; Stulak, John M.; Teuteberg, J.; Vierecke, Juliane; Schueler, Stephan; D’Alessandro, David A.

doi:10.1016/j.healun.2020.01.1329

Cited by 81 publications

(126 citation statements)

References 210 publications

Supporting

Mentioning

125

Contrasting

Order By: Relevance

“…Advanced medical therapy, last-generation pacemakers, and defibrillators have changed the clinical evolution of HF [9,11,12,[22][23][24]. However, 0.5-5% of patients are refractory to any optimized medical therapy and develop advanced HF.…”

Section: The History Clinical Requirement For and Technology Of Vadsmentioning

confidence: 99%

“…However, 0.5-5% of patients are refractory to any optimized medical therapy and develop advanced HF. Analyses from the United States of America (USA) suggest that 250,000-300,000 patients under the age of 75 years suffer from advanced systolic HF (defined as New York Heart Association (NYHA class IIIb-IV)) [1,3,22,23]. In Europe, 500,000 patients are likely to be suffering from HF [6,[9][10][11][12]24].…”

Section: The History Clinical Requirement For and Technology Of Vadsmentioning

confidence: 99%

“…Long-term LVADs have been used for several years in both acute and chronic refractory HF, mostly as a bridge to Htx. Technology improvements, together with the shortage of donors, have recently led to the adoption of LVADs in a much extended range of patients [6][7][8][9][10][11][12]23,24].…”

Section: The History Clinical Requirement For and Technology Of Vadsmentioning

confidence: 99%

“…In the USA, implantation rates are collected by the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry [1,[3][4][5]23]. Currently, over 2500 devices are implanted in North America every year.…”

Section: Pumpsmentioning

confidence: 99%

“…All axial-flow pumps provide full circulatory support [6][7][8][9][10][11][12]23,24]. Thoratec Corporation, Jarvik Heart, MicroMed Cardiovascular, and Berlin Heart are the main companies manufacturing these systems, and all have obtained CE approval.…”

Section: Axial Flowmentioning

confidence: 99%

See 4 more Smart Citations

Durable Continuous-Flow Mechanical Circulatory Support: State of the Art

Loforte

Botta

Boschi

et al. 2021

Hearts

View full text Add to dashboard Cite

Implantable mechanical circulatory support (MCS) systems for ventricular assist device (VAD) therapy have emerged as an important strategy due to a shortage of donor organs for heart transplantation. A growing number of patients are receiving permanent assist devices, while fewer are undergoing heart transplantation (Htx). Continuous-flow (CF) pumps, as devices that can be permanently implanted, show promise for the treatment of both young and old patients with heart failure (HF). Further improvement of these devices will decrease adverse events, enable pulse modulation of continuous blood flow, and improve automatic remote monitoring. Ease of use for patients could also be improved. We herein report on the current state of the art regarding implantable CF pumps for use as MCS systems in the treatment of advanced refractory HF.

show abstract